Sponsors for KIN Research:

Google Groups
Subscribe to Medical Schools & Immunology Programs
Visit this group


The KIN Consulting & Research Services Company

   The KIN Consulting and Research Services Company sells the analysis and visions of Chairman Natto (Published April 21st, 2006):

Join our campaign by submitting a complaint to the SEC! "SEC Contact Form" (Click HERE)

                        Chairman's Views on The Antibiotics Related Industry

   The simple truth of the matter is that the Pharmaceutical Industry is going to have a rather drastic slide.   The fact is that there is a disease that is killing white blood cells.   As the disease grows, the source for new antibodies subsequently declines.   They are inversely correlated  (rate of disease vs rate of new antibodies).   As a result there will be a drop in earnings forecasts, which will make it harder to raise money for the pharmaceutical companies.   This risk was not mentioned in the 20 F Form of the following company.

   It is as if they do not know that the solution is theoretically The KIN Intravenous Solution (Glucose + Cloned White Blood Cells).   If anybody needs more information on the protocols for ex vivo production of white blood cells, then please contact the Chairman at khalidnatto@gmail.com.

                 Chairman's Research on "Bayer Corporation" (BAY)

Bayer Corporation (BAY)
Bayer Corporation Graph source Edgar Online Pro on April 20th, 2006

  The Following data is sourced from Yahoo Finance & the ANNUAL REPORT ON FORM 20-F For the Year Ended December 31, 2005 . The overview of the company was:



Bayer AG offers pharmaceuticals, diagnostics and health care products, agricultural products, and polymers. It operates in three groups: HealthCare, CropScience, and MaterialScience. The HealthCare group engages in the development, production, and marketing of prescription pharmaceuticals and biological products; over-the-counter medications and nutritional supplements; diagnostic products for laboratory testing, near-patient testing, and self-testing applications; and veterinary medicines, nutritionals, and grooming products for companion animals and livestock. The CropScience group develops and markets a portfolio of fungicides, herbicides, insecticides, and seed treatment products; and a range of products for the green industry, garden care, nonagricultural pest and weed control and conventional seeds, and plant biotechnology industries. The MaterialScience group primarily develops, manufactures, and markets plastic granules, methylcellulose, metallic and ceramic powders, and semifinished products; and polyurethanes, as well as coating and adhesive raw materials and basic inorganic chemicals. The company distributes its products through distributors, governmental agencies, wholesalers, pharmacies, and hospitals, as well as directly to patients in Europe, North America, Asia/Pacific, Latin America, Africa, and the Middle East. Bayer AG, formerly known as Farbenfabriken Bayer AG, was founded in 1863 and is headquartered in Leverkusen, Germany.

                            Highlights of Risks Related to Our (BAY) Business

   For further detail please review the 20 F Form in detail.

1. Cyclicality may reduce our operating margins or cause operating losses.

2. Failure to develop new products and production technologies may harm our competitive position.

3. Regulatory controls and changes in public policy may reduce the profitability of new or current products.

4. Our operating margins may decrease if we are not be able to pass increased raw material prices on to customers or if prices for our products decrease faster than raw material prices.

5. Shortages or disruptions of supplies to customers due to unplanned capacity decreases or shutdowns of production plants may reduce sales.

6. Litigation and administrative claims could harm our operating results and cash flows.

7. Competition from generic pharmaceuticals after patent expiration may reduce market share and sales revenue.

8. The loss of patent protection or ineffective patent protection for marketed products may result in loss of sales to competing products.

9. Failure to compete successfully or weak performance by our marketing partners may reduce our operating results.

10. Our transactions relating to LANXESS expose us to continuing liability.

11. Risks from the handling of hazardous materials could negatively impact our operating results.

12. Environmental liabilities and compliance costs may have a significant negative effect on our operating results

13. Existing insurance coverage may turn out to be inadequate.

14. Significant fluctuations in exchange rates affect our financial results.

15. Negative developments affecting capital markets may make additional contributions to our pension funds necessary and changes in the yield assumptions could have an impact on the valuation of liabilities.

Recent articles on the medical industry:

For New Research Projects Contact The Chairman at Email: khalidnatto@gmail.com

First name:
Last name:
Email address:
Address 1:
Address 2:
Zip code:
Request information on product?


Disclaimer of Warranty and Limitation of Liability
The information, products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.  The KIN Consortium does not warrant the information or services provided herein or your use of this web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties, including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose. The KIN Consortium  will not be responsible for any loss or damage that could result from interception by third parties of any information or services made available to you via this web site. Although the information provided to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium  cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors, officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any other party involved in making this web site, the data contained herein or the products or services offered on this web site available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN Consortium  or of any vendor providing software or services. In no event will The KIN Consortium  or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental damages or any other damages of any kind even if The KIN Consortium  or any other such party has been advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator errors, strikes or other labor problems. The KIN Consortium  cannot and does not guarantee continuous, uninterrupted or secure access to the web site.

Proprietary Rights
All right, title and interest in this web site and any content contained herein is the exclusive property of The KIN Consortium , except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and you may print, copy and download any information or portion of this web site for your personal use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer, or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior written approval. If you copy or download any information or software from this web site, you agree that you will not remove or obscure any copyright or other notices or legends contained in any such information.

The KIN Consortium and other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium . The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags on other pages or sites on the World Wide Web without the written permission of The KIN Consortium  or such third party, which may own the marks.

Pursuant to Section 512(c)(2) of the Copyright Act, The KIN Consortium  designates the following agent to receive notifications of claimed infringement: Khalid I Natto, The KIN Consortium , Email:
kalnatto2000@yahoo.com, Website: http://khalidnatto.tripod.com 

Use of Links
This web site contains links to third party web sites. These links are provided only as a convenience. The inclusion of any link is not and does not imply an affiliation, sponsorship, endorsement, approval, investigation, verification or monitoring by The KIN Consortium of any information contained in any third party web site. In no event shall The KIN Consortium be responsible for the information contained on that site or your use of or inability to use such site. You should also be aware that the terms and conditions of such site and the site's privacy policy may be different from those applicable to your use of this web site.

Feedback, subscriptions, ideas? Email: kalnatto2000@yahoo.com